A conference of the MIT Laboratory for Financial Engineering
October 26-28, 2016
CanceRx 2016 is an invitation-only conference hosted by MIT in collaboration with the National Cancer Institute and with the participation of the American Cancer Society, focusing on new approaches to financing biomedical innovation in oncology and other areas. Although we are seeing incredible scientific advancements on a near-daily basis, there are still a number of challenges facing the biopharma industry and the drug development process. To explore these challenges and potential solutions for addressing them, the conference will bring together representatives from key stakeholder communities including academia and medical research centers, community hospitals, the biopharma industry, health plans, NIH/NCI, the FDA, patient advocacy groups, investment banks, hedge funds, biotech VCs, and institutional and retail investors.
The conference will be organized as a series of panel discussions with substantial audience participation, focused on topics that will include:
- Updates on successful fundraising initiatives and their business models
- Potential business implications of scientific and clinical breakthroughs
- Prioritizing and evaluating scientific research
- Clinical trial design, big data, and implications for commercialization
- Drug pricing and patient access to transformative therapies
- The changing role of policymakers, the public sector, and venture philanthropy
- Innovations in intellectual property rights management and licensing structures
In addition, an optional executive education program, “Basic Financial Analysis for Life Sciences Professionals,” will be offered from 12:00 to 4:00pm on Wednesday, October 26, followed by the welcome dinner at 6:00pm. Space for this educational program is limited to 100 participants on a first-come-first-served basis.[This text is here for extra space][This text is here for extra space]
Conference Steering Committee: David B. Agus, University of Southern California; Margaret Anderson, FasterCures; Anna Barker, Arizona State University; Douglas A. Dachille, AIG; Jacob Goldfield; Robert Langer, MIT; Pablo Legorreta, Royalty Pharma; Judy Lewent; J. Leonard Lichtenfeld, American Cancer Society; Frank McCormick, University of California San Francisco; Terry McGuire, Polaris Partners; Robert C. Merton, MIT Sloan School of Management; Lita Nelsen; Larry Norton, Memorial Sloan-Kettering Cancer Center; Phillip A. Sharp, MIT; Stephen Kennedy Smith, Park Agency; Marty Tenenbaum, Cancer Commons; Jake Xia, Harvard Management Company.
If you have any questions, please contact Jayna Cummings, firstname.lastname@example.org or 617-258-5727.